Form 4: Perspective Therapeutics Director Receives Stock Option Grant
SEC Form 4 Filing
Robert F. Williamson III, a director at Perspective Therapeutics, Inc., was granted a stock option to purchase 50,000 shares of common stock.
Summary
- Robert F. Williamson III, a director of Perspective Therapeutics, Inc. (CATX), received a stock option grant on March 3, 2025.
- The option allows him to purchase 50,000 shares of common stock at an exercise price of $2.46 per share.
- The option vests in full on March 3, 2026, contingent upon Williamson's continued service.
- The option expires on March 3, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects a standard compensation practice, indicating confidence in the company's future performance.
Positives
- The stock option grant aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.
- The vesting period encourages continued service and commitment to the company.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the option.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
- Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their directors and officers.
- The size of the grant (50,000 shares) and the vesting schedule (one year) appear to be within typical ranges for director-level equity awards at companies of similar size and stage of development.
Stakeholder Impact
- The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.
- The grant incentivizes the director to make decisions that benefit the company and its stakeholders.
Key Dates
| Date | Description |
|---|---|
| February 12, 2025 | Option grant approved by the Issuer's Board of Directors |
| March 3, 2025 | Grant date of the stock option and date of earliest transaction |
| March 3, 2026 | Option vests in full, subject to continued service |
| March 3, 2035 | Expiration date of the stock option |
| March 5, 2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.